EUVIMEDEUVIMED entdecken
FallberichtÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities

Thalia G Newman, Jason S Knight iD

Arthritis & Rheumatology · 2025-12 · 77 (12) · 1626-1634

DOI: 10.1002/art.43258 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Arthritis & Rheumatology, online erschienen am 27.07.2025. Verfasst von Thalia G Newman und 1 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan Medical School, Ann Arbor. Hauptthemen laut MEDLINE: Antibodies, Antiphospholipid, Antiphospholipid Syndrome. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid syndrome (APS) is an autoimmune thromboinflammatory disease characterized by vascular thrombosis, pregnancy morbidity, and other manifestations driven by antiphospholipid autoantibodies. In this review, we present a clinical case that illustrates some diagnostic and therapeutic challenges in managing severe, relapsing APS manifestations, including microvascular injury and diffuse alveolar hemorrhage. We then discuss recent advances in our understanding of APS pathophysiology, emphasizing the critical role of anti–β‐2 glycoprotein I antibodies in triggering cell‐specific inflammatory and thrombotic pathways. Finally, we speculate that achieving definitive disease control will ultimately require strategies that eliminate or effectively neutralize these pathogenic antibodies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, AntiphospholipidAntiphospholipid SyndromeAdultFemaleHumansbeta 2-Glycoprotein IThrombosis

Substanzen

Antibodies, Antiphospholipidbeta 2-Glycoprotein I

Autor:innen und Institutionen

  • University of Michigan Medical School, Ann Arbor.

ORCID-Profile: Jason S Knight

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Newman, T. G., & Knight, J. S. (2025). Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities. Arthritis & Rheumatology, 77(12), 1626-1634. https://doi.org/10.1002/art.43258

Vancouver

Newman TG, Knight JS. Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities. Arthritis & Rheumatology. 2025;77(12):1626-1634. doi:10.1002/art.43258

BibTeX
@article{Newman2025,
  author = {Newman, Thalia G and Knight, Jason S},
  title = {Antiphospholipid Syndrome: An Antibody‐Mediated Disease With Emerging Therapeutic Opportunities},
  journal = {Arthritis & Rheumatology},
  year = {2025},
  volume = {77},
  number = {12},
  pages = {1626--1634},
  doi = {10.1002/art.43258}
}
Kostenlos starten →